OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection and stabilization devices, announced that it has entered into definitive agreements to acquire CoreBiome. The transactions are expected to close […]
4D pharma plc (AIM: DDDD) and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to evaluate 4D’s Live Biotherapeutic oncology pipeline across a range of cancer settings. The alliance brings […]
In just a few short years, Rebiotix has taken the concept of “bugs as drugs” and turned it into actual practice, constructing a standardized, stabilized drug product from the broad consortia of microbes present in a […]
Seres Therapeutics, Inc. (Nasdaq:MCRB) today announced that it has enrolled the first patient in its Phase 2B trial, ECO-RESET, evaluating microbiome development candidate SER-287 in patients with active mild-to-moderate ulcerative colitis. Seres has received $40 […]
AOBiome Therapeutics, Inc. (“AOBiome”), a leading clinical-stage microbiome company focusing on the research and development of a novel class of drugs for inflammatory conditions, central nervous system disorders, and other systemic diseases, announced that the […]
Da Volterra, a clinical-stage microbiome company focused on developing new therapeutics to protect the intestinal microbiota, announced today that it has enrolled the first patients in a Phase 2 trial called SHIELD, evaluating its innovative […]
ExeGi Pharma announced positive results from a recent study conducted at the Clinic of Small Animal Medicine at Ludwig Maximilian University (LMU) in Munich, Germany and the Department of Small Animal Clinical Sciences at Texas […]
Locus Biosciences Inc., a biotechnology company developing precision antibacterial therapies, announced that it has entered into an exclusive collaboration and license agreement with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson […]
Synthetic Biologics, Inc. (NYSE American: SYN), announced that the first two patients have been enrolled in SYN-010’s Phase 2b investigator-sponsored clinical study. SYN-010 is a proprietary, modified-release reformulation of lovastatin lactone designed to reduce methane […]
New findings from a Giellepi Health Science Division (Giellepi S.p.A) clinical research trial demonstrates that a mixture of probiotic strains and lactoferrin could aid in reducing the most common cause of vaginal discomfort in women. […]
Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, announced it has entered into a collaboration agreement with the […]